Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc.verified

ATRA

Price:

$0.661

Market Cap:

$78.90M

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of...[Read more]

Industry

Biotechnology

IPO Date

2014-10-16

Stock Exchange

NASDAQ

Ticker

ATRA

The PE Ratio as of April 2024 (TTM) for Atara Biotherapeutics, Inc. (ATRA) is -0.25

According to Atara Biotherapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.25. This represents a change of -58.27% compared to the average of -0.60 of the last 4 quarters.

Atara Biotherapeutics, Inc. (ATRA) Historical PE Ratio (quarterly & annually)

How has ATRA PE Ratio performed in the past?

The mean historical PE Ratio of Atara Biotherapeutics, Inc. over the last ten years is -4.65. The current -0.25 PE Ratio has changed 437.71% with respect to the historical average. Over the past ten years (40 quarters), ATRA's PE Ratio was at its highest in in the June 2022 quarter at 10.72. The PE Ratio was at its lowest in in the March 2015 quarter at -24.87.

Quarterly (TTM)
Annual

Average

-4.65

Median

-4.63

Minimum

-11.81

Maximum

-0.20

Atara Biotherapeutics, Inc. (ATRA) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Atara Biotherapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 147.96%

Maximum Annual PE Ratio = -0.20

Minimum Annual Increase = -86.58%

Minimum Annual PE Ratio = -11.81

Quarterly (TTM)
Annual
YearPE RatioChange
2023-0.20-86.58%
2022-1.47-66.24%
2021-4.34-8.36%
2020-4.7463.07%
2019-2.90-55.98%
2018-6.6045.84%
2017-4.52-12.36%
2016-5.16-56.29%
2015-11.81147.96%
2014-4.76-42.91%

Atara Biotherapeutics, Inc. (ATRA) Average PE Ratio

How has ATRA PE Ratio performed in the past?

The current PE Ratio of Atara Biotherapeutics, Inc. (ATRA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-2.00

5-year avg

-2.73

10-year avg

-4.65

Atara Biotherapeutics, Inc. (ATRA) PE Ratio vs. Peers

How is ATRA’s PE Ratio compared to its peers?

Atara Biotherapeutics, Inc.’s PE Ratio is greater than Fate Therapeutics, Inc. (-3.12), greater than Sana Biotechnology, Inc. (-5.34), greater than Caribou Biosciences, Inc. (-3.44), greater than Arcus Biosciences, Inc. (-3.56), greater than Heron Therapeutics, Inc. (-3.60), greater than Allogene Therapeutics, Inc. (-1.81), greater than BioXcel Therapeutics, Inc. (-0.46), greater than Karyopharm Therapeutics Inc. (-0.94), greater than X4 Pharmaceuticals, Inc. (-1.89), greater than HOOKIPA Pharma Inc. (-0.89), greater than Mereo BioPharma Group plc (-11.51), less than Galera Therapeutics, Inc. (-0.15), greater than Acumen Pharmaceuticals, Inc. (-3.61), greater than VectivBio Holding AG (-7.94), greater than Icosavax, Inc. (-8.27), greater than Apellis Pharmaceuticals, Inc. (-10.90), greater than iTeos Therapeutics, Inc. (-3.36), greater than TScan Therapeutics, Inc. (-4.97),

Build a custom stock screener for Atara Biotherapeutics, Inc. (ATRA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Atara Biotherapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Atara Biotherapeutics, Inc. (ATRA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Atara Biotherapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Atara Biotherapeutics, Inc.'s PE Ratio?

How is the PE Ratio calculated for Atara Biotherapeutics, Inc. (ATRA)?

What is the highest PE Ratio for Atara Biotherapeutics, Inc. (ATRA)?

What is the 3-year average PE Ratio for Atara Biotherapeutics, Inc. (ATRA)?

What is the 5-year average PE Ratio for Atara Biotherapeutics, Inc. (ATRA)?

How does the current PE Ratio for Atara Biotherapeutics, Inc. (ATRA) compare to its historical average?